Natco Pharma rallies up to 6% as Delhi HC judgement paves way to launch generic version of ‘Risdiplam'

Roche’s appeal before the Appellate Bench of the Delhi Court was announced today, dated October 9, 2025, as the appeal was refused, and consequently the status quo has been removed.

"Today, in a landmark decision, the Commercial Appellate Division of the Hon’ble Delhi High Court dismissed an appeal filed by the Swiss pharmaceutical company F. Hoffmann-La Roche AG," the press release added.

With arguments spanning over several months, a Ld. Single Judge of the Hon’ble Delhi High Court, in a groundbreaking judgement dated 24.03.2025, paved the way for Natco to launch a generic version of the drug ‘Risdiplam’, which is used for the treatment of the debilitating disease Spinal Muscular Atrophy (SMA). SMA is one of the leading causes of death in infants related to the degeneration of neurones, the pharma company said in its press release.

"Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. The Ld. Single Judge had factored in the challenge of the invalidity of Roche’s patent and laid special emphasis on the public interest, considering the Swiss company’s pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients," the press release added.

Natco Pharma has decided to launch the product with immediate effect and price the product at ₹15,900 MRP, consistent with the company’s stand before the court. The company also intends to offer some discount to certain deserving patients through its patient access programme.

About Natco Pharma

Natco Pharma, headquartered in Hyderabad, develops, manufactures and distributes generic and branded pharmaceuticals, speciality pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company is an R&D-orientated and science-driven leading oncology player in the targeted therapies of the domestic market and focuses on limited-competition molecules in the US.

The pharma company has nine manufacturing sites and two R&D facilities in India. The company’s differentiated manufacturing facilities are approved by several leading regulatory authorities like the US FDA, Brazil ANVISA, Health Canada, WHO and others, catering to 50+ global markets.